Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15536657 | 1.00 | ERN1 (0.42) | ERN1ALDH1A1MAPTKDM4ECYP3A4 | |
| SCHEMBL28187916 | 0.84 | MAPT (0.42) | ERN1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10179458 | 0.83 | MAPT (0.35) | ERN1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29709737 | 0.83 | MAPT (0.35) | ERN1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10179459 | 0.83 | MAPT (0.35) | ERN1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1414171 | 0.82 | PIN1 (0.43) | ALDH1A1MAPTCYP19A1PIN1MEN1 | |
| SCHEMBL1414175 | 0.82 | PIN1 (0.43) | ALDH1A1MAPTCYP19A1PIN1MEN1 | |
| SCHEMBL26690214 | 0.81 | MAPT (0.36) | ALDH1A1MAPTCYP3A4MEN1KMT2A | |
| SCHEMBL586888 | 0.80 | MAPT (0.40) | ALDH1A1MAPTPIN1MEN1KMT2A | |
| SCHEMBL31161596 | 0.80 | ALDH1A1 (0.35) | ALDH1A1MAPTCYP3A4PIN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3472162-B1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10654867-B2 | Heteroaryl estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-20150336948-A1 | Isotopically Labeled Biaryl Urea Compounds | MERCK SHARPE & DOHME CORP. | 2015-11-26 | — | — | US | disclosed |
| US-20150336948-A1 | Isotopically Labeled Biaryl Urea Compounds | MERCK SHARPE & DOHME CORP. | 2015-11-26 | — | — | US | disclosed |
| EP-2855477-A1 | ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013181075-A1 | ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | ERN1 2381/4885ALDH1A1 3885/4885MAPT 3/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | ERN1 2406/4885ALDH1A1 3804/4885MAPT 1/4885 |
| US-20150336948-A1 | Isotopically Labeled Biaryl Urea Compounds | MAPT, SLC14A1, UBTF | ERN1 2670/4885ALDH1A1 2226/4885MAPT 1/4885 |
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESRRA | ERN1 2075/4885ALDH1A1 1204/4885MAPT 1088/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | ERN1 2381/4885ALDH1A1 3885/4885MAPT 3/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | ERN1 1948/4885ALDH1A1 3566/4885MAPT 13/4885 |
| US-10654867-B2 | Heteroaryl estrogen receptor modulators and uses thereof | ESR2, GPER1, ESRRA | ERN1 2075/4885ALDH1A1 1204/4885MAPT 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.